• About the Journal
    Exploration of Targeted Anti-tumor Therapy (eISSN 2692-3114), a peer-reviewed, open access online journal, publishes articles on all aspects of cancer research, including clinical diagnosis and analysis, case report, prevention, intervention treatment, pre-clinical and clinical trials of all types of cancers. Submissions with good originality, well-designed experiments and rigorous data are particularly welcomed.
    From the Editors-in-Chief
    It is a particularly exciting time to be involved in cancer research and I am delighted to take on the role of co-Editor-in-Chief of the new journal Exploration of Targeted Anti-tumor Therapy. The journal will provide a platform for publication of studies on all aspects of the development of targeted anti-cancer drugs and will appeal to a broad range of readers. I look forward to receiving submissions of your manuscripts describing cutting-edge research in this fast moving and important field.
    Graham Packham
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    I am really honored to take on the role of co-Editor-in-Chief of this new journal—Exploration of Targeted Anti-tumor Therapy. Like many colleagues, I spent a large part of my professional life researching new cancer therapies. The efforts of the scientific community have allowed the development of targeted therapies to affect significantly the course of the main tumors. In this scenario, ETAT wants to represent a platform for discussion and evaluation on all aspects related to the development of targeted therapies, from the identification of the target to its validation and clinical exploration, including the evaluation of biomarkers of activity and toxicity. We therefore await your contributions to build together a place of confrontation that favors scientific progress in the field of target therapies.
    Nicola Normanno
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    Latest Articles
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains...
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Online First: October 28, 2020 Explor Target Antitumor Ther. 2020;1:Online First
    DOI: https://doi.org/10.37349/etat.2020.00019
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:6
    Download:1
    Times Cited: 0
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c...
    Giulia Meoni ... Angela Stefania Ribecco
    Online First: October 28, 2020 Explor Target Antitumor Ther. 2020;1:Online First
    DOI: https://doi.org/10.37349/etat.2020.00022
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:42
    Download:2
    Times Cited: 0
    Open Access
    Original Article
    Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
    Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamox...
    Milene Volpato ... Valerie Speirs
    Online First: October 19, 2020 Explor Target Antitumor Ther. 2020;1:Online First
    DOI: https://doi.org/10.37349/etat.2020.00021
    View:145
    Download:6
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” to bind to a protein of interest, connected by a chemical linker...
    Robert I. Troup ... Matthias G. J. Baud
    Online First: October 11, 2020 Explor Target Antitumor Ther. 2020;1:Online First
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:345
    Download:52
    Times Cited: 0